Esophageal Cancer Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Esophageal Cancer Market is segmented By Type (Adenocarcinomas, Gastrointestinal Stromal Tumors, Carcinoid Tumors, Squamous Cell Carcinoma, Other), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Esophageal Cancer Market Overview

The Global Esophageal Cancer Market report analyses the shares, size, recent trends, future market outlook, and competitive intelligence. Esophageal cancer is a condition in which cancer cells form in the tissues of the esophagus. Demand for esophageal cancer drugs in the USA is rising. The competitive rivalry intensifies with Amgen Inc., Eli Lilly, and Company, and others active in the market.

Esophageal cancer is a condition in which cancer cells form in the tissues of the esophagus. Smoking, excess alcohol, and Barrett's esophagus can raise the risk of esophageal cancer. Signs and indications of esophageal cancer are weight loss and pain or trouble swallowing.

The esophagus is the hollow, muscular tube that passes food and liquid from the neck to the abdomen. The esophagus surface comprises many layers of tissue, including mucous membrane, muscle, and connective tissue. This cancer starts on the interior lining of the esophagus and flows outward within the other layers as it progresses.

When esophageal cancer is detected in the early stage, there is a greater probability of recovery. Esophageal cancer is usually in an advanced stage when it is diagnosed. At succeeding stages, esophageal cancer can be treated but infrequently can be cured. Exerting part in one of the clinical trials being done to recover treatment should be considered.

Esophageal Cancer Market Summary

For More Insights Request Free Sample

Esophageal Cancer Market Dynamics

The esophageal cancer market growth is driven by the rise in cases of esophageal cancer which creates an opportunity for pharma companies to introduce novel therapy and promising pipeline drugs. In addition, advances in the treatment rate and the adoption of a sedentary lifestyle are some of the impacting factors for the demand for esophageal cancer drugs.

Increasing research and development for the treatment of cancer will drive the market growth

Rising research and development and launches of novel products by key players are significant constituents that are expected to drive the growth of the global esophageal cancer market in the forecast period. Increasing research and development for new drug discovery for the treatment of esophageal cancer is expected to drive the growth of the esophageal cancer drug market size significantly.

For instance, in February 2021, researchers at Case Western Reserve University discovered that blocking two molecular pathways that send signals inside cancer cells could reduce esophageal adenocarcinoma, the most common esophageal malignancy in the U.S. These findings suggest JNK/TGF-beta-targeted therapy as a new treatment approach to treat esophageal cancer.

The government of several economies and various non-government organizations are taking initiatives to increase patient awareness about esophageal cancer. Research related to esophageal cancer has recently caught the consideration of oncologists and experts. The enormous scale of disease types associated with esophageal cancer is behind the revitalized interest of the medical fraternity. Moreover, increased consumption of carcinogens existing in specific foods has also become a concern for oncologists. Therefore, the growth of the global esophageal cancer market mainly hinges on the efforts taken by the medical organization to alleviate the occurrence of esophageal cancer.

The prevalence of achalasia is expected to drive the growth of the esophageal cancer market growth

The significant risk factors that lead to esophageal cancer include age, gender, tobacco, alcohol, Barrett's esophagus, obesity, and achalasia. These factors will increase the demand for esophageal cancer drugs over the forecast period. For instance, according to a study published by National Center for Biotechnology Information in 2017, achalasia patients have a 50 times more prominent risk of esophageal squamous cell carcinoma than the general population. The overall predominance of achalasia is 9 to 10 in 100,000 people annually worldwide.

The rising prevalence of disorders like adenocarcinoma and squamous cell carcinoma in the US also contributes to the market’s growth in the forecast period. In addition, the consecutive occurrence of GERD causes dysplasia, eventually resulting in the uncontrolled growth of cells in the esophagus. This factor will further increase the esophageal cancer market in the forecast period.

Side Effects associated with Certain Medications Coupled with High Cost of Cancer Treatment

The side effects begun by esophageal cancer drugs are loss of hunger and weight loss, weakness, diarrhea, sore mouth, hair loss, low blood cell counts, hand-foot syndrome, blood clots (deep vein thrombosis), heart damage, and nervous system damage. According to the report published by the American Cancer Society (ACS) in 2017, the side effects of esophageal cancer drugs such as Cisplatin, oxaliplatin, docetaxel, and paclitaxel can cause significant damage to nerves outside the brain and spinal cord.

The high cost of therapy in the treatment of esophageal cancer will hamper the market growth in the forecast period. For instance, according to the report published by HealthDay, cancer patients paid US$ 207,000 per year for their treatment and medicines, while in 1995, the cost was US$ 54,100 per year.

COVID-19 Impact on Esophageal Cancer Market Growth

Reports suggest a higher risk of COVID-19 infection with associated severe morbidity and mortality in cancer patients. The complexity of the multidisciplinary approach to esophageal cancer patients and the high morbidity rates of esophageal surgery has challenged the treatment pathways of these patients.

According to Oxford Academics, the surgery of patients who have cancer was limited to 24 (36.9%) patients in 6 (50%) centers, mostly due to the deficiency of anesthesiologists and occupation of intensive care unit beds from intubated COVID-19 patients. Implications for neoadjuvant chemo (radio) therapy were increased in 14% of patients. Separate COVID-19 hospital pathways were active in 11 (91.7%) units. COVID-19 screening protocols covered nasopharyngeal swabs in 91.7%, chest computed tomography scan in 8.3%, and the particular use of lung ultrasound in 75% of units. Postoperative interstitial pneumonia occurred in 1 (1.5%) patient.  

Esophageal Cancer Market Segment Analysis

By type, the Esophageal Cancer Market is classified as adenocarcinomas, gastrointestinal stromal tumors, carcinoid tumors, squamous cell carcinoma, and others.

The gastrointestinal stromal tumors segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)   

Gastrointestinal stromal tumors (GISTs) are unusual cancers that arise in specific cells on the surface of the gastrointestinal (GI) tract, which is also known as the digestive tract. The GI tract prepares food for energy and rids the body of fixed waste.

The food and gastric juices are then discharged into the small intestine. The small intestine continues busting down the food and absorbing most of the nutrients into the bloodstream. Some GISTs seem to be much more likely than others to grow into other areas or spread to other parts of the body.

GISTs Cancers can occur anywhere in the GI tract, from the throat to the anus. Most cancers that start in the GI tract, including most esophagus cancers, stomach cancers, and colon and rectum cancers, start in the gland cells that line almost all GI tracts. The malignancies that develop in these cells are called adenocarcinomas.

The GI tract also has neuroendocrine cells. These cells have some features in common with nerve cells but also have other features in common with hormone-producing (endocrine) cells. Cancers that develop from these cells are called neuroendocrine tumors (NETs). These cancers are rare in the GI tract. Carcinoid tumors are an example of neuroendocrine tumors found in the GI tract.

Based on therapy, the esophageal cancer market is classified into targeted therapy, radiation therapy, immunotherapy, and chemotherapy.

Based on therapy, the esophageal cancer market is classified into targeted therapy, immunotherapy, and chemotherapy.

The chemotherapy segment is expected to dominate the esophageal cancer market during the forecast period  

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells' cause may be many side effects during therapy.

Esophageal Cancer Market Geographical Share

North American region holds the largest market share global Esophageal Cancer Market

North American region is dominating the global esophageal cancer market and accounted for the largest market share in 2021, owing to the growing prevalence of esophageal cancer in this region. For instance, the American Cancer Society’s report projected that around 17,650 new esophageal cancer cases will be diagnosed (13,750 in men and 3,900 in women) in the U.S. by 2021.

Numerous cancer research institutes and Universities have linked their synergies to develop a stable method for treating melanoma. Case Western Reserve University in the United States, in the initial quarter of 2021, developed a pathway that can restrain the occurrence of esophageal cancer. The research was based on testimony collected from an extended series of examinations. Such advancements are expected to develop the possibilities of growth in the esophageal cancer market in the region.

On the other hand, Asia-Pacific is anticipated to manifest the most agile growth rate over the forecast period due to the rise in clinical trials in Asian countries for innovative drugs to treat esophageal cancer. For instance, National Cancer Center Hospital, Tokyo, started a clinical trial in December 2018, which estimated the comparative study between combination therapy with inference DCF (docetaxel plus cisplatin and 5-fluorouracil) versus absolute chemo-radiotherapy for locally advanced carcinoma of the thoracic esophagus.

Esophageal Cancer Market Companies and Competitive Landscape

The esophageal cancer market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., Eli Lilly and Company, Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Genentech Inc., Sanofi-Aventis Merck & Co. Among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the esophageal cancer market globally.    

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

Product Portfolio: The Company’s portfolio is comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

Why Purchase the Report?

• Visualize the composition of the esophageal cancer market segmentation by type, therapy, route of administration, and end-user highlighting the key commercial assets and players.
• Identify commercial opportunities in the esophageal cancer market by analyzing trends and co-development deals.
• Excel data sheet with thousands of data points of esophageal cancer market-level 4/5 segmentation.
• PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
• Product mapping in excel for the key product of all major market players

The global esophageal cancer market report would provide access to approx. 69 market data tables, 62 figures, and 180 pages.